A recently published case report co-authored by ABVT diplomates Dr. Leah Swanson and Dr. Renee Schmid documents an unusual poisoning in a dog that ingested ruxolitinib phosphate, the active ingredient in the prescription topical cream Opzelura. Ruxolitinib is a Janus kinase (JAK) inhibitors used in the treatment of eczema and vitiligo in people.
The report, "Clinical manifestations reported in a canine after ingesting ruxolitinib phosphate (Opzelura)", describes a dog that developed cardiovascular and ocular abnormalities after exposure to the 1.5% topical cream. The authors—working with colleagues at Pet Poison Helpline/SafetyCall International and Blue Pearl Pet Hospital—detail the exposure history, clinical presentation, diagnostic findings, and treatment, and situate ruxolitinib within its broader pharmacologic class, drawing comparisons to related medications used in veterinary practice.
As topical human medications like ruxolitinib become more common in households, the report offers veterinarians a valuable reference for recognizing and managing accidental ingestions in pets.